Found 98 results in Expert Content

Summary: Bernie Clark, VP of Marketing and Strategy for Catalent Biologics, discusses the challenges and risks associated with this undertaking and the collaboration and innovation necessary to help combat coronavirus in this Q&A.

Summary: Catalent Biologics presents a case study on the investigational COVID-19 therapeutic candidate, lenzilumab, and its development from gene to late stage clinical trials.

Summary: Enzymes can be challenging to express and scale up to become biologic therapies.  In order to develop their optimized tissue plasmigen activator (tPA) to treat patients with hemorrhagic stroke...

Summary: Which 11 biotech startups stand out from the pack that have launched in 2020? Watch the Endpoints 11 - Startups to Watch Awards, a virtual event celebrating innovative science and entrepreneurship.

Summary: Hear Catalent Biologics Region President, address challenges in manufacturing scale-up and discuss how partnerships are enabling pharma companies of all sizes to meet unprecedented timelines as they race toward delivering vaccines to patients worldwide.

Summary: Download this webinar to learn how our RED-106 noncleavable maytansine linker-payload is well-tolerated, offering wider therapeutic windows compared to other technologies.

Summary: Learn why speed and efficiency are top priorities for companies looking to develop a clonal cell line for drug substance manufacturing.

Summary: Experts provide an update on their partnership to enable and expedite scale-up to large-scale manufacturing and how it can be applied to future vaccine development.

Summary: Biologic drug substance development and biomanufacturing is a critical step in the long, complex pathway to approval. There are many considerations to be made around...

Summary: R&D execs discuss how they've reorganized global teams, tapped new programs to fight COVID-19 and plan for the future after the pandemic.